Colon Cancer Treatment by Stage

This page is for people with colon cancer and their families. It explains how stage is worked out and what treatment usually looks like at each stage, plus questions to ask and signs that need urgent care.

Colon cancer stage comes from the AJCC TNM system, 8th edition. AJCC stands for the American Joint Committee on Cancer. Three separate questions get answered, then combined.

T is how deep the tumor has grown through the bowel wall. The wall has layers, and the T number tracks which one has been breached.

• Tis: carcinoma in situ (abnormal cells that have not spread), confined to the mucosa, the inner lining. It has not grown through the muscularis mucosae, a thin muscle layer under the lining.
• T1: through the muscularis mucosae into the submucosa, the layer under the lining.
• T2: into the muscularis propria, the thick muscle layer.
• T3: through the muscularis propria into the fatty tissue around the colon.
• T4a: through the visceral peritoneum, the outer membrane.
• T4b: directly invading another organ or structure.

N is how many lymph nodes contain cancer.

• N0: no nodes involved.
• N1: one to three nodes positive, counting deposits of 0.2 mm or more.
• N2a: four to six nodes positive.
• N2b: seven or more nodes positive.

M is whether it has spread to distant sites. M0 means no, M1 means yes.

Combined: stage 0 is Tis N0 M0. Stage I is T1 or T2, N0, M0. Stage II is T3 or T4 with no nodes: IIA is T3, IIB is T4a, IIC is T4b. Stage III is any T with positive nodes. Stage IV is any M1.

One number on your pathology report is worth checking. Guidance calls for at least 12 lymph nodes to be examined before anyone can confidently say the nodes are clear. If your report shows fewer, ask whether that changes the staging conversation. If a cancer is staged too low, it may be treated too lightly.

Stage 0 is the most superficial lesion, limited to the mucosa. Because it has not invaded, the operation can be limited, sometimes to removal during colonoscopy.

Stage I means the tumor has reached the submucosa or the muscle layer but no nodes are involved. Standard treatment is surgical removal of the segment with clear margins, then joining the two ends back together, called anastomosis. Chemotherapy is not routine.

Here surgery is again the main treatment, wide removal and anastomosis. Whether to add chemotherapy afterward is still debated. Chemotherapy given after surgery is called adjuvant chemotherapy. The National Cancer Institute's PDQ summary describes it for stage II as under clinical evaluation rather than standard.

Some stage II cancers carry higher risk. Features that raise concern include the tumor sticking to nearby structures, a perforation through the bowel wall, and a complete blockage of the bowel when the cancer is found.

Ask for MMR or MSI testing before this decision. These tests check whether the tumor's DNA repair system (mismatch repair) is working. The NCI summary notes that MSI-high status has been linked with better survival in earlier-stage disease. Ask how your result affects the plan.

If you are offered chemotherapy for stage II, ask: what is my estimated benefit in percentage points, and over what time frame? The NCI summary says pooled studies suggested a 2% to 4% improvement in survival with 5-FU-based chemotherapy. It also says chemotherapy after surgery is not indicated for most people with stage II unless they join a clinical trial. The choice is one to make with your oncologist.

With positive lymph nodes, surgery plus chemotherapy is the standard of care. The MOSAIC trial compared FOLFOX-4, which adds oxaliplatin to 5-FU and leucovorin, against the same regimen without oxaliplatin, over 6 months. FOLFOX produced longer overall survival in stage III.

That established oxaliplatin-based chemotherapy after surgery as the standard for stage III colon cancer.

The IDEA collaboration pooled six randomized trials, enrolling 13,025 people with stage III colon cancer between 2007 and 2015. It compared 3 months against 6 months of FOLFOX or CAPOX (capecitabine plus oxaliplatin).

Overall, 3 months did not formally prove non-inferior (proven to work about as well as 6 months). Three-year disease-free survival was 74.6 percent with 3 months and 75.5 percent with 6 months.

The nerve damage difference is large. Grade 2 or worse neurotoxicity occurred in 16.6 percent on 3 months of FOLFOX and 14.2 percent on 3 months of CAPOX. On 6 months, the figures were 47.7 percent and 44.9 percent. That is roughly a threefold difference. The NCI summary notes the high rate of disabling nerve damage (neuropathy).

The subgroup results split by regimen. With FOLFOX, 6 months was better than 3. With CAPOX, 3 months performed like 6.

So the real question to ask is not just "how long," but "which regimen, and at what risk level." IDEA was a pooled non-inferiority analysis (a study testing whether a shorter course is not meaningfully worse), not a rulebook. Its findings interact: the shorter course looked strongest with CAPOX and in lower-risk disease, defined by T and N stage. It does not translate into a fixed prescription. How long you are treated is a trade-off between a possible small loss of benefit with 3 months and a definite higher risk of side effects, especially nerve damage, with 6 months. It is weighed against your other health problems and what you want. Ask where your T and N stage puts you, which regimen is proposed, and what the difference in benefit would be for you specifically. Then tell your team how you weigh that trade.

Stage IV means the cancer has spread to distant sites, such as the liver.

Treatment options listed include surgery, systemic therapy, immunotherapy, and clinical trials. For liver-only disease, options include removing the metastases, chemotherapy first to shrink them so they become removable, local ablation (destroying tumors with heat or cold), and chemotherapy delivered into the hepatic artery, the main blood vessel to the liver.

Ask whether your tumor has been tested for MMR/MSI, RAS and BRAF before systemic treatment starts. The NCI summary ties some treatments to these results, such as anti-EGFR antibodies for RAS wild-type tumors, encorafenib with cetuximab for BRAF V600E, and immunotherapy for MSI-H.

• How many lymph nodes were examined, and how many were positive?
• Were the surgical margins clear, and by how much?
• Was there perforation, obstruction, or invasion into nearby structures?
• Has MMR or MSI testing been done, and what did it show?
• If chemotherapy is proposed, which regimen, how many months, and what is the estimated benefit for me?
• Who is following me afterward, and on what scan and blood test schedule?

Call 911 or go to an emergency department for heavy rectal bleeding, black tarry stools, or vomiting blood (MedlinePlus). Do the same if a surgical wound splits open. Call 911 as well for sudden shortness of breath or chest pain, especially with a swollen, painful calf (MedlinePlus). Do not drive yourself.

Call your care team right away, at any hour, for any of these. If you cannot reach your team, or the problem is severe, call 911 or your local emergency number.

• Belly pain with vomiting and no gas or stool passing.
• Fever of 100.4 F (38 C) or higher while on chemotherapy.
• A surgical wound that drains, or becomes hot and red.
• A swollen, painful calf without breathing trouble.
• Any visible blood in your stool that is not heavy (MedlinePlus).

Metastatic Colorectal Cancer: What Now?, MSI-H Colorectal Cancer, Cancer Staging, and Chemotherapy.

• https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq
• https://seer.cancer.gov/statfacts/html/colorect.html